Browse the evidence

Oral semaglutide significantly reduces blood glucose levels (HbA1c) and improves glycemic control in patients with Type 2 Diabetes compared to placebo and other active comparators.

If you have Type 2 Diabetes and struggle with injections, oral semaglutide is a proven option. Start with a low dose (3mg daily) for a month, then increase to 7mg or 14mg based on your blood sugar needs. It effectively lowers HbA1c levels and helps manage cardiovascular risk.

GLP-1 analogues (liraglutide, semaglutide, tirzepatide, efpeglenatide) combined with lifestyle interventions produce significant weight loss (5-15%) and reduce cardiometabolic risk in adults with obesity.

GLP-1 medications like semaglutide and liraglutide are effective tools for weight loss when combined with diet and exercise. They work by slowing digestion and reducing appetite. While gastrointestinal side effects like nausea are common, they often subside. These drugs are approved for adults with high BMI or obesity-related comorbidities.

Administration of GLP-1 receptor agonists (semaglutide 2.4 mg weekly or liraglutide 3.0 mg daily) combined with lifestyle interventions significantly reduces body weight and modulates gut microbiota composition in adults with obesity.

If you have obesity, GLP-1 medications like semaglutide (2.4 mg weekly) or liraglutide (3.0 mg daily) are highly effective for weight loss when combined with lifestyle changes. They work by mimicking hormones that regulate blood sugar and gut health, leading to significant weight reduction and improved metabolic markers.

Tirzepatide (5, 10, and 15 mg) is a cost-effective treatment for weight management compared to liraglutide in the UK, demonstrating dominance (cost savings and QALY gains) in the general obesity trial population and favorable ICERs in the specific NICE-reimbursed population.

For patients in the UK with obesity or overweight plus complications, tirzepatide (5, 10, or 15 mg weekly) combined with diet and exercise is a cost-effective treatment option compared to liraglutide. It offers potential cost savings and quality-of-life gains, and unlike liraglutide which is restricted to specialist services, tirzepatide can be prescribed in primary care.

Tirzepatide reduces the incidence of obesity-related complications, specifically knee replacements (29-46% reduction) and type 2 diabetes (25-48% reduction), compared to liraglutide.

Tirzepatide treatment is associated with significantly lower rates of knee replacements and type 2 diabetes compared to liraglutide, likely due to greater weight loss and prediabetes reversal.

Dual incretin agonists (e.g., tirzepatide) and newer GLP-1 receptor agonists (e.g., semaglutide) provide superior glycaemic control and greater weight reduction compared to earlier GLP-1 agents.

If you have Type 2 Diabetes, newer injectable medications like tirzepatide or semaglutide are significantly more effective at lowering blood sugar and reducing weight than older GLP-1 drugs. Discuss these options with your doctor, especially if you are struggling with weight or glucose control despite previous treatments.

Long-acting GLP-1 receptor agonists (semaglutide and dulaglutide) provide superior efficacy, particularly in cardio-renal protection, and overall value compared to other long-acting GLP-1RAs in China, earning strong clinical recommendations.

For patients with Type 2 Diabetes in China, Semaglutide and Dulaglutide are the preferred long-acting GLP-1 receptor agonists. They offer strong recommendations due to superior efficacy, particularly in protecting the heart and kidneys, and better overall value. While newer drugs like Tirzepatide show great potential for weight loss and glucose control, their high cost and lack of insurance coverage make them less accessible. Patients should discuss these options with their doctors, prioritizing agents with established cardiovascular benefits and insurance coverage.

Treatment with tirzepatide (10-15 mg weekly) causes significant shifts to lower BMI categories in adults with obesity, which is associated with substantial improvements in cardiometabolic risk factors including blood pressure, fasting insulin, and lipid profiles.

If you have obesity or overweight with related health issues like high blood pressure or high cholesterol, talk to your doctor about tirzepatide. It is a once-weekly injection that helps many people move to a lower BMI category, which is linked to better heart health and metabolic markers. It works best when combined with a reduced-calorie diet and increased physical activity.

Tirzepatide, a dual GLP-1 and GIP receptor agonist, produces significant weight loss (exceeding 20% body weight in some cases) and improves glycemic control in patients with type 2 diabetes and obesity.

Tirzepatide is a weekly injection that mimics gut hormones to significantly reduce weight (often >20%) and improve blood sugar. It works best when paired with diet and exercise. Start with lower doses to minimize stomach issues like nausea, which usually improve over time.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces significant weight loss (8.6% to 20.9%) and metabolic improvements in obese patients, outperforming placebo and demonstrating superior efficacy compared to semaglutide in head-to-head comparisons.

Tirzepatide is a once-weekly injection that helps obese patients lose significant weight (up to 20%) and improves blood sugar and heart risk factors. It works by mimicking hormones that regulate appetite and digestion. While it can cause temporary stomach issues like nausea, it is generally well-tolerated and more effective than some other existing weight-loss drugs. Medical supervision is required to manage dosing and side effects.

Performing aerobic exercise in the afternoon/evening improves blood glucose levels more effectively than morning exercise in individuals with Type 2 Diabetes.

If you have Type 2 Diabetes, schedule your aerobic workouts for the afternoon or evening. This timing has been shown to lower blood glucose levels more effectively than morning exercise. Note: If you have Type 1 Diabetes, morning exercise might be safer to avoid delayed nighttime hypoglycemia.

GLP-1 agonists (semaglutide 2.4 mg SC weekly and tirzepatide 5-15 mg SC weekly) produce profound weight loss (15-21% body weight reduction) in overweight/obese adults, significantly outperforming placebo and existing pharmacologic strategies like metformin.

If you are struggling with significant weight gain, particularly from psychiatric medications, GLP-1 agonists like semaglutide or tirzepatide offer the most effective pharmacological solution currently available, capable of producing 15-20% body weight loss. These require weekly injections and lifestyle changes, and while they cause transient gastrointestinal side effects, their efficacy far exceeds older options like metformin. Consult your provider to see if you qualify based on BMI and medical history.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, demonstrates superior glycemic control and weight loss compared to semaglutide and insulin degludec in patients with Type 2 Diabetes.

If you have Type 2 Diabetes and struggle with blood sugar control and weight loss despite other medications, ask your doctor about tirzepatide (Mounjaro). This weekly injection targets two hormones (GIP and GLP-1) and has been shown to be more effective than semaglutide and insulin degludec in lowering blood sugar and reducing weight.

GLP-1 receptor agonists (specifically semaglutide 2.4 mg and liraglutide 3.0 mg) are the most effective pharmacotherapeutic interventions for weight loss in adults with obesity, significantly outperforming placebo and other agents.

For adults with obesity, GLP-1 receptor agonists like semaglutide (2.4 mg weekly) and liraglutide (3.0 mg daily) are the most effective medication options for weight loss, producing significantly greater weight reduction than placebo or other drugs. While gastrointestinal side effects like nausea are common, the overall safety profile is favorable, making these a promising treatment option when lifestyle changes alone are insufficient.

Semaglutide (2.4 mg weekly) produces significantly greater weight loss (15.8%) compared to liraglutide (6.4%) in patients without type 2 diabetes.

If you are struggling with weight loss despite diet and exercise, semaglutide (Wegovy) is currently the most effective registered medication, offering about 15.8% average weight loss over 68 weeks when combined with lifestyle changes. It is taken as a once-weekly injection, which is less frequent than daily options like liraglutide.

Weekly subcutaneous semaglutide (2.4 mg) produces significantly greater mean weight loss (15.4%) compared to daily subcutaneous liraglutide (3.0 mg, 6.4%) in patients with overweight or obesity.

If you are struggling with obesity, talk to your doctor about Semaglutide. It is a once-weekly injection that has been shown to help people lose significantly more weight than older medications like Liraglutide. Start with a low dose to minimize side effects and work your way up to the full dose over several months.

Tirzepatide (TZP) reduces the risk of four-component major adverse cardiovascular events (MACE-4) in patients with type 2 diabetes (T2DM) and obesity compared to placebo, with the 15mg dose showing the most significant reduction.

If you have T2DM or obesity, Tirzepatide (TZP) can significantly lower your risk of major cardiovascular events (like heart attack or stroke) compared to a placebo. The 15mg dose is the most effective for heart protection, but it also comes with a higher risk of side effects like nausea. Patients with T2DM seem to get more heart benefits and fewer side effects than those with obesity alone. Talk to your doctor about whether the cardiovascular benefits outweigh the potential side effects for you.

Antiobesity medications (AOMs), particularly GLP-1/GIP receptor agonists like semaglutide and tirzepatide, are effective adjuncts to lifestyle modifications for achieving clinically significant weight loss (>5-10% total body weight) in patients with BMI >30 (or >27 with comorbidities).

If you have a BMI over 30 (or 27 with health issues), lifestyle changes alone may not be enough for lasting results. Talk to your doctor about GLP-1/GIP medications like semaglutide or tirzepatide. These are weekly injections that help with appetite and satiety. They work best when combined with diet and exercise changes, and your doctor should monitor your nutrition to prevent deficiencies.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces clinically meaningful weight loss (average 15-25% over 88 weeks) superior to placebo and semaglutide in adults with obesity or overweight.

If you have obesity or overweight with related health issues, Tirzepatide is an FDA-approved, once-weekly injection that works by mimicking gut hormones to reduce appetite and improve metabolism. Clinical trials show it leads to significant weight loss (up to 25% over nearly 2 years), often more than other popular drugs like semaglutide. It requires a calorie-restricted diet and exercise. Common side effects are gastrointestinal (nausea/diarrhea), but serious risks are rare. It is contraindicated for those with a history of medullary thyroid cancer.

New incretin-based anti-obesity drugs (GLP-1, GIP, and triple agonists) achieve weight loss magnitudes (up to 25%) comparable to bariatric surgery by enhancing satiety and inhibiting hunger through central nervous system mechanisms.

If lifestyle changes alone aren't enough, newer incretin-based medications (like semaglutide or tirzepatide) are highly effective, offering weight loss up to 25% by targeting hunger and satiety signals in the brain. They are taken as weekly injections and are intended for long-term use, similar to how other chronic conditions are managed. While costly, they offer a non-surgical alternative with efficacy approaching bariatric surgery.

Tirzepatide, a dual GIP/GLP-1 receptor agonist administered once weekly, produces superior glycemic control and weight loss compared to other current pharmacotherapies for type 2 diabetes.

Tirzepatide is a once-weekly injection that helps lower blood sugar and lose weight more effectively than many current diabetes drugs. It works by mimicking hormones that regulate insulin and appetite. While nausea is a common side effect, most people tolerate it well, and only a small percentage stop taking it. It is particularly useful for those who struggle with weight gain from other diabetes medications.

Multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 receptor agonists (orforglipron) are emerging treatments that reduce body weight and improve metabolic health.

Newer multi-receptor agonists (tirzepatide, retatrutide) and oral GLP-1 agonists (orforglipron) are in clinical trials or recently approved, offering once-weekly or daily options to reduce body weight and improve cardiac metabolism in adults with obesity.

Phenotype-guided pharmacotherapy (matching drug mechanism to obesity phenotype) yields significantly greater weight loss than non-phenotype-guided approaches.

If you are struggling with obesity, ask your doctor about 'phenotyping.' Instead of just taking the most common weight loss drug, see if your specific type of hunger (e.g., emotional, hormonal, or slow metabolism) matches a specific medication. This personalized matching has been shown to result in significantly more weight loss than standard approaches.

Tirzepatide (5-15 mg once weekly) produces superior weight loss (16.5% to 22.4%) and glycemic control compared to GLP-1 monotherapies (liraglutide, semaglutide) and other glucose-lowering medications in patients with type 2 diabetes and obesity.

For adults with obesity or type 2 diabetes, tirzepatide (5-15 mg weekly) is a highly effective treatment that significantly reduces body weight (up to ~21%) and improves cardiovascular risk factors more than GLP-1 monotherapies like semaglutide or liraglutide. It requires weekly injections and lifestyle changes, with side effects like nausea being common but usually mild and temporary during dose increases.